Insight Molecular Diagnostics
IMDX
60 hedge funds and large institutions have $78.5M invested in Insight Molecular Diagnostics in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 12 closing their positions.
213% more call options, than puts
Call options by funds: $447K | Put options by funds: $143K
211% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 9
193% more capital inflows, than outflows
Capital inflows: $5.03M | Capital outflows: $1.72M
2.29% more ownership
Funds ownership: 46.53% → 48.82% (+2.3%)
2% more funds holding
Funds holding: 59 → 60 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.44M |
| 2 |
Pura Vida Investments
New York
|
+$477K |
| 3 |
State Street
Boston,
Massachusetts
|
+$455K |
| 4 |
BlackRock
New York
|
+$383K |
| 5 |
Penbrook Management
New York
|
+$357K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Phoenix Financial
Givatayim,
Israel
|
-$426K |
| 2 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$375K |
| 3 |
P.A.W. Capital
Greenwich,
Connecticut
|
-$278K |
| 4 |
ETF Managers Group
Summit,
New Jersey
|
-$226K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$73.5K |
IMDX Hedge Fund Activity: Q4 2020 in Review
60 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2020, worth a combined $78.5M — up 80% from $43.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IMDX positions and 12 closed out — a net gain of 1 holder — while 28 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.44M. The largest seller was Phoenix Financial, exiting entirely with an estimated $426K sold.
- 60 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2020, up from 59 in Q3 2020.
- Funds reported $78.5M of Insight Molecular Diagnostics stock for Q4 2020, up 80% quarter-over-quarter.
- 13 funds opened new Insight Molecular Diagnostics positions in Q4 2020 and 12 closed out, a net change of +1 holder.
- The largest Insight Molecular Diagnostics buyer in Q4 2020 was Vanguard Group, an estimated $1.44M added.
- The largest Insight Molecular Diagnostics seller in Q4 2020 was Phoenix Financial, an estimated $426K sold.
Based on aggregated 13F filings for Q4 2020.